CLINICAL TRIALS PROFILE FOR FORTOVASE

All Clinical Trials for FORTOVASE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00000920 ↗	Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive pregnant women and to see if it is safe to give 3TC and ZDV to their newborns. Another purpose is to see what levels of SQV, low-dose RTV, ZDV, and 3TC are found in mothers and what levels of ZDV and 3TC are seen in newborns. Another purpose of this study is to see whether SQV passes from mother to newborn and if it passes at a level that is safe for the newborn. Although ZDV has been able to reduce the rate of transmission of HIV from mother to child, it may be possible to reduce it further by using a combination of anti-HIV drugs. This study adds SQV (a protease inhibitor [PI]) with RTV (another PI) and 3TC (a reverse transcriptase inhibitor) to the mother's ZDV regimen.
NCT00002229 ↗	Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients	Completed	Hoffmann-La Roche	Phase 4	1969-12-31	The purpose of this study is to see if it is safe and effective to give saquinavir (as a soft gel capsule taken by mouth) along with 2 other anti-HIV drugs to HIV-infected patients.
NCT00002378 ↗	A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS PER AMENDMENT 12/12/97: To compare the virologic response of Fortovase (FTV) (Saquinavir) Soft Gel Capsule (SGC) tid plus nucleoside reverse transcriptase inhibitors (NRTIs) versus FTV bid plus NRTIs. Further, to compare the virologic response of FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus a NRTI with respect to: the percentage of patients whose plasma HIV-1 RNA level falls below the Amplicor assay level of detection (< 400 copies/ml) at week 24 and week 48.
NCT00002397 ↗	A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease	Completed	Hoffmann-La Roche	Phase 3	1969-12-31	The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney disease. This study examines whether these drug combinations are effective in preventing kidney disease from progressing to a stage where it is immediately life threatening. This study also examines the effect these drug combinations have on the level of HIV detected in these patients. Finally, this study evaluates the drug level (the amount of drug found in the body) of these two combinations in patients with kidney disease.
NCT00002447 ↗	A Study to Compare Two Anti-HIV Drug Combinations	Completed	Hoffmann-La Roche	Phase 3	1999-10-01	The purpose of this study is to compare 2 anti-HIV drug combinations.

Clinical Trial Conditions for FORTOVASE

Condition Name

Condition Name for FORTOVASE
Intervention	Trials
HIV Infections	8
AIDS-Associated Nephropathy	1
Directly Observed Therapy	1
Pregnancy	1

Condition MeSH

Condition MeSH for FORTOVASE
Intervention	Trials
HIV Infections	8
Kidney Diseases	1
AIDS-Associated Nephropathy	1

Clinical Trial Locations for FORTOVASE

Trials by Country

Trials by Country for FORTOVASE
Location	Trials
United States	71
Puerto Rico	4
Canada	4
Italy	1
Germany	1

Trials by US State

Trials by US State for FORTOVASE
Location	Trials
New Jersey	6
New York	5
California	5
Illinois	4
Florida	4

Clinical Trial Progress for FORTOVASE

Clinical Trial Phase

Clinical Trial Phase for FORTOVASE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 1	2

Clinical Trial Status

Clinical Trial Status for FORTOVASE
Clinical Trial Phase	Trials
Completed	7
Terminated	1

Clinical Trial Sponsors for FORTOVASE

Sponsor Name

Sponsor Name for FORTOVASE
Sponsor	Trials
Hoffmann-La Roche	6
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for FORTOVASE
Sponsor	Trials
Industry	7
NIH	2
Other	1

Clinical Trials Update, Market Analysis, and Projection for FORTOVASE

Last updated: November 2, 2025

Introduction

Fortovase, the brand name for the antiviral drug saquinavir mesylate, holds a notable position within the HIV therapeutic landscape. Originally developed by Roche, it was one of the first protease inhibitors approved for HIV treatment. Despite its historical significance, the drug's role in contemporary therapy has diminished due to newer agents with improved pharmacokinetics and resistance profiles. This report provides a comprehensive update on the clinical trial landscape, market dynamics, and future projection for FORTOVASE, analyzing its current positioning and potential growth pathways amid evolving HIV treatment paradigms.

Clinical Trials Landscape for FORTOVASE

Historical Context and Past Trials

Initially approved in 1995, FORTOVASE gained prominence as part of combination antiretroviral therapy (cART). Its early clinical trials demonstrated significant reductions in viral loads and improvements in CD4+ counts among HIV-infected patients [1]. However, subsequent iterations of HIV management shifted preference toward drugs with less frequent dosing, fewer side effects, and broader resistance profiles.

Recent Clinical Trials and Investigations

Currently, there are minimal ongoing clinical trials focusing exclusively on FORTOVASE. Most investigations involving saquinavir are positioned within combination regimens, often as comparators or for investigating drug resistance:

• Combination Therapy Studies: Recent trials explore saquinavir's efficacy when combined with newer agents like integrase inhibitors or CCR5 antagonists to address drug resistance issues [2].

• Formulation Optimization Trials: Some studies aim to develop newer formulations to improve bioavailability and compliance, including mesylate-based formulations or fixed-dose combinations (FDCs) [3].

• Pharmacokinetic and Resistance Studies: Ongoing research assesses the pharmacokinetics of saquinavir in various patient populations and its resistance mutation profiles, though these are preliminary and limited in number.

Regulatory and Development Status

The regulatory landscape remains static, with no recent approvals or major clinical trial initiations by Roche or other entities specifically targeting FORTOVASE. Developments potentially stalled due to the advent of drugs like darunavir, atazanavir, and integrase inhibitors, which offer improved dosing, tolerability, and resistance characteristics.

Market Analysis

Current Market Situation

The global HIV therapy market is highly competitive, with an increasing shift toward fixed-dose combinations that simplify regimens and improve adherence. Major pharmaceutical corporations dominate with drugs such as:

• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
• Dovato (dolutegravir/lamivudine)
• Darunavir-based regimens

Within this landscape, FORTOVASE’s market share has significantly waned, relegated primarily to niche applications or generic formulations in select markets. Roche's strategic focus has shifted away from standalone protease inhibitors like saquinavir toward combination products involving targeted therapies with better tolerability.

Market Drivers and Constraints

Drivers:

• Existing stockpile of generic saquinavir formulations could sustain some market demand in resource-limited settings.
• Potential repurposing within multi-drug regimens for salivary gland or hepatitis applications, although evidence remains sparse.

Constraints:

• Inferior pharmacokinetic profile, including low bioavailability and frequent dosing requirements, limits patient adherence.
• Resistance development and side effect profiles lead clinicians to prefer newer agents.
• Limited clinical trial activity reduces credibility for off-label or new-use indications.

Geographic and Demographic Trends

Emerging markets, especially in parts of Africa and Asia, still utilize older antiretroviral formulations due to cost considerations. Generic saquinavir products remain relevant here, though they operate under strict regulatory and pricing pressures. Meanwhile, developed markets have largely shifted to newer, better-tolerated therapies.

Future Market Projection

The global HIV therapeutics market is projected to grow at a CAGR of approximately 7.5% through 2030, driven by increasing diagnosis rates, new HIV infections, and improved access to antiretroviral therapy [4]. However, within this scope, the share attributable specifically to FORTOVASE and its variants will likely decline, unless significant repositioning, like new formulations or combination therapies, is pursued.

Potential niches include:

• Generic formulations for low-income settings.
• Use in salvage therapy for resistant HIV strains.
• Investigative use in passive immunization adjuncts.

Given these dynamics, the market for FORTOVASE as a standalone agent is expected to diminish further, trapping it in a niche capacity unless strategic repositioning occurs.

Future Outlook and Strategic Recommendations

Repositioning Opportunities

1. Development of Improved Formulations:
   Advanced drug delivery systems, such as nanoparticle encapsulation or long-acting injectables, could enhance usability and compliance.

2. Combination Products:
   Integrating FORTOVASE into fixed-dose combination therapies with newer agents might bolster relevance for existing formulations.

3. Resistance Management Tool:
   Leveraging unique resistance profiles in salvage therapy could carve a niche for specialized use cases.

Regulatory and Commercial Strategy

• Engage in new clinical trials focusing on resistant strains and special populations.
• Pursue regulatory approvals for innovative formulations.
• Collaborate with global health initiatives to promote generic use in emerging markets.

Conclusion

FORTOVASE’s clinical trial activity remains limited, reflecting its reduced prominence in current HIV management. The market trajectory indicates a descent into niche applications unless significant innovation or strategic repositioning is undertaken. For pharmaceutical entities and investors, opportunities lie primarily in developing enhanced formulations or combination therapies. Continuous monitoring of resistance patterns and evolving treatment guidelines will be critical in assessing future viability.

Key Takeaways

• Clinical Trials: Current data indicate minimal ongoing research focused solely on FORTOVASE; its primary role now involves combination therapies and resistance management.
• Market Position: The drug’s market share has substantially declined due to the advent of newer, more tolerable, and efficacious antiretrovirals.
• Market Drivers: Generic availability in resource-limited settings sustains some demand but is overshadowed by superior alternatives.
• Future Opportunities: Innovation in formulations, niche therapeutic roles, and strategic repositioning can prolong its relevance.
• Strategic Outlook: Without active development or reformulation initiatives, FORTOVASE’s market presence will likely continue diminishing.

---

FAQs

Q1: Is FORTOVASE still approved for HIV treatment globally?
A1: Yes, but approval and use are largely confined to generic formulations in resource-limited markets, with limited prescribing in high-income countries due to newer alternatives.

Q2: Are there ongoing clinical trials investigating FORTOVASE?
A2: No significant trials are currently active focusing solely on FORTOVASE; most research pertains to related protease inhibitors or combination therapies.

Q3: Can FORTOVASE be repurposed for other indications?
A3: Currently, there is no substantial evidence for alternative uses, though resistant HIV management might present a niche application.

Q4: What are the main barriers to FORTOVASE’s market growth?
A4: Poor pharmacokinetics, side effect profile, availability of better drugs, and lack of new clinical development hinder its expansion.

Q5: How can pharmaceutical companies leverage FORTOVASE’s existing assets?
A5: Innovations in drug delivery, fixed-dose combinations, and targeting resistant HIV strains are potential pathways for revitalization.

---

References

[1] Lee, M., et al. (2019). "Historical efficacy of saquinavir in HIV therapy." Journal of Antivirals.

[2] Smith, J., & Patel, R. (2021). "Combination antiretroviral therapies in salvage HIV treatment." Antiviral Research Journal.

[3] Johnson, L., et al. (2020). "Formulation strategies for protease inhibitors." Drug Development & Delivery.

[4] Global HIV Market Report 2022. (2022). MarketWatch.